- 期刊
從文獻探討中藥治療新型冠狀病毒疾病的可能性
The Possibility of Using Traditional Chinese Medicine for the Treatment of COVID-19: A Narrative Review
摘要
面對新型冠狀病毒疾病的大流行，目前尚未有特效藥可供治療，因此找出對抗病毒有效的中藥亦為重要的研究方向。2003年中國爆發嚴重急性呼吸系統症候群（SARS）冠狀病毒感染的期間曾採用中藥治療，發現常規醫療結合中藥有助於改善SARS病人症狀及肺部浸潤吸收的速度。此外，桑菊飲加玉屏風散是常用來預防病毒感染的處方。根據先前的研究，中藥具有對抗新型冠狀病毒潛力的藥物包括甘草、大黃、魚腥草、板藍根、陳皮、黃芩、丹參等，中成藥則有雙黃連口服液、連花清瘟膠囊、金花清感膠囊、臺灣清冠一號等。上述中藥可能的作用機轉包括抑制新型冠狀病毒棘狀蛋白與angiotensin-converting enzyme 2（ACE2）受體結合、抑制病毒複製過程3-胰凝乳蛋白酶樣蛋白酶與ribonucleic acid（RNA）依賴性RNA聚合酶，降低促炎性細胞因子，產生抗病毒、抗發炎及免疫調節作用。中藥治療新型冠狀病毒感染的研究目前大多是基於有限的細胞與動物實驗，將來仍需進行更多的隨機雙盲對照試驗來提供臨床療效的可靠證據。
並列摘要
In the face of the COVID-19 pandemic, there is still a lack of miracle drugs for treatment. Repurposing drugs such as Remdesivir and corticosteroids to treat COVID-19 are being studied. Traditional Chinese medicine was widely used during the outbreak of Severe Acute Respiratory Syndrome (SARS) coronavirus infection in China in 2003. It was found that standard medical treatment combined with Chinese medicine treatment may improve the symptoms of SARS patients and speeding resolution of lung infiltration. The commonly used prescriptions for preventing the coronavirus infection are Sangjuyin plus Yupingfeng powder. Various Traditional Chinese medicines with potential to fight SARS-CoV-2 include Liquorice Root and Rhizome, Rhubarb, Heartleaf Houttuynia Herb, Indigowoad Root, Tangerine Peel, Scutellaria Root, and Red Sage Root and Rhizome etc.. In addition, Chinese patent medicines including Shuanghuanglian Oral liquid, Lianhua Qingwen Capsule, Jinhua Qinggan Granule and Taiwan Chingguan Yihau are recognized as plausible agents for the treatment of novel coronavirus pneumonia. The antiviral, anti-inflammatory and immunomodulatory effects of selected Chinese herbal drugs may attribute to their inhibiting the binding of the coronavirus spike protein to the angiotensin-converting enzyme 2 (ACE2) receptor, inhibiting key enzymes such as 3-chymotrypsin-like protease and ribonucleic acid (RNA)- dependent RNA polymerase during viral replication, and reducing pro-inflammatory cytokines. Since most of the relevant studies mentioned the potential anti-SARS-CoV-2 activity of these agents were only in vitro and animal experiments, more randomized double-blind controlled trials are needed to provide reliable evidence of clinical efficacy in future.